Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASTR: Reprieve DMS vs Optimal Diuretic Therapy in ADHF
NCT05174312Completed
- Sponsor
- Reprieve Cardiovascular
- Start
- Jul 2022
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Randomised, open-label trial in heart failure (HF) (2 arms), sponsored by Reprieve Cardiovascular. Primary endpoints: Total Urine Sodium Output at 24 hours and Clinically Significant Acute Kidney Injury, Severe Electrolyte Abnormality, Symptomatic Hypotension or Hypertensive Emergency. Started Jul 2022; status: completed.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT05174312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174312.